



AMENDMENTS TO THE CLAIMS

Please replace the currently pending claims with the following listing of claims:

1-43. **(Canceled)**

44. **(Previously presented)** The method according to claim 46, wherein the subject is human.

45. **(Canceled)**

46. **(Currently amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from ~~about~~ amino acid 46 to ~~about~~ amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 in an effective amount.

47. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID No:1 or SEQ ID NO:2 in an effective amount.

48. **(Currently amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody which binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas ~~A6C12.11~~, A6F8.6, A8G3.5, ~~A19A10.30~~, A10B2.18, ~~A17A2.16~~, and B3F6.17 bind in an effective amount.

49. **(Canceled)**

50. **(Currently amended)** The method according to claim 46, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors cells.

51-58. **(Canceled)**

59. **(Previously presented)** The method of claim 46, wherein the antibody is a humanized antibody.

60. **(Previously presented)** The method of claim 46, wherein the antibody is a human antibody.

61. **Canceled.**

62. **(Currently amended)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from ~~about~~ amino acid 46 to ~~about~~ amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 and a pharmaceutically acceptable carrier.

63. **(Previously presented)** The method of claim 46, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab'; and a F(ab')₂ fragment.

64. **(Previously presented)** The method of claim 46, wherein the antibody is a full length antibody.

65. **(Previously presented)** The method of claim 46, wherein the antibody is a single chain antibody.

66. **(Previously presented)** The method of claim 46, wherein the antibody is conjugated to a chemotherapeutic agent.

67. **(Previously presented)** The method of claim 46, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

68. **(Previously presented)** The method of claim 66, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

69. **(Previously presented)** The method of claim 68, wherein the agent is a maytansinoid.

70. **(Currently amended)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from ~~about~~ amino acid 46-62 of SEQ ID NO:1 or 2, wherein the antibody is conjugated to a maytansinoid, and a pharmaceutically acceptable carrier.

71. **(Previously presented)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.

72. **(Previously presented)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal, antibody that specifically binds to an epitope of Cripto to which an antibody produced by hybridoma B3F6.17 binds, and a pharmaceutically acceptable carrier.

73. **(Previously presented)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that, specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 and is capable of internalizing Cripto.

74. **(Previously presented)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID NO:1 or SEQ ID NO:2, and a pharmaceutically acceptable carrier.

75. **(Currently amended)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas ~~A6.C12.11~~, A8G3.5, and A6F8.6 bind, and a pharmaceutically acceptable carrier.

76. **(Previously presented)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 and inhibits the interaction of Cripto and ALK4.

77. **(Currently amended)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas ~~A6C12.11~~, A6F8.6, A8G3.5, ~~A19A10.30~~, A10B2.18, ~~A17A2.16~~, and B3F6.17 bind, and a pharmaceutically acceptable carrier.

78-80. **(Canceled)**

81. **(Currently amended)** A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of ~~Cripe~~ Cripto to which an antibody produced by hybridoma A10B2.18 binds, and a pharmaceutically acceptable carrier.

82. **(Currently amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from ~~about~~ amino acid 46-62 of SEQ ID NO:1 or 2, wherein the antibody is conjugated to a maytansinoid, in an effective amount.

83. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a humanized version of the antibody produced by the hybridoma B3F6.17 in an effective amount.

84. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma B3F6.17 binds in an effective amount.

85. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma A10B2.18 binds in an effective amount.

86. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and is capable of internalizing Cripto in an effective amount.

87. **(Currently amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6.C12.11, A8G3.5, and A6F8.6 bind in an effective amount.

88. **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and inhibits the interaction of Cripto and ALK4 in an effective amount.

89. **(Previously presented)** The method according to claim 47, wherein the subject is human.

90. **(Previously presented)** The method according to claim 47, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

91. **(Previously presented)** The method of claim 47, wherein the antibody is a humanized antibody.

92. **(Previously presented)** The method of claim 47, wherein the antibody is a human antibody.

93. **(Previously presented)** The method of claim 47, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

94. **(Previously presented)** The method of claim 47, wherein the antibody is a full length antibody.

95. **(Previously presented)** The method of claim 47, wherein the antibody is a single chain antibody.

96. **(Previously presented)** The method of claim 47, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

97. **(Previously presented)** The method of claim 47, wherein the antibody is conjugated to a chemotherapeutic agent.

98. **(Previously presented)** The method of claim 97, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

99. **(Previously presented)** The antibody of claim 98, wherein the agent is a maytansinoid.

100. **(Previously presented)** The method according to claim 48, wherein the subject is human.

101. **(Previously presented)** The method according to claim 48, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

102. **(Previously presented)** The method of claim 48, wherein the antibody is a humanized antibody.

103. **(Previously presented)** The method of claim 48, wherein the antibody is a human antibody.

104. **(Previously presented)** The method of claim 48, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

105. **(Previously presented)** The method of claim 48, wherein the antibody is a full length antibody.

106. **(Previously presented)** The method of claim 48, wherein the antibody is a single chain antibody.

107. **(Previously presented)** The method of claim 48, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

108. **(Previously presented)** The method of claim 48, wherein the antibody is conjugated to a chemotherapeutic agent.

109. **(Previously presented)** The method of claim 108, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

110. **(Previously presented)** The antibody of claim 109, wherein the agent is a maytansinoid.

111. **(Previously presented)** The method according to claim 62, wherein the subject is human.

112. **(Previously presented)** The method according to claim 62, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

113. **(Previously presented)** The method of claim 62, wherein the antibody is a humanized antibody.

114. **(Previously presented)** The method of claim 62, wherein the antibody is a human antibody.

115. **(Previously presented)** The method of claim 62, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

116. **(Previously presented)** The method of claim 62, wherein the antibody is a full length antibody.

117. **(Previously presented)** The method of claim 62, wherein the antibody is a single chain antibody.

118. **(Previously presented)** The method of claim 62, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

119. **(Previously presented)** The method of claim 62, wherein the antibody is conjugated to a chemotherapeutic agent.

120. **(Previously presented)** The method of claim 119, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

121. **(Previously presented)** The antibody of claim 120, wherein the agent is a maytansinoid.

122. **(Previously presented)** The method according to claim 70, wherein the subject is human.

123. **(Previously presented)** The method according to claim 70, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

124. **(Previously presented)** The method of claim 70, wherein the antibody is a humanized antibody.

125. **(Previously presented)** The method of claim 70, wherein the antibody is a human antibody.

126. **(Previously presented)** The method of claim 70, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

127. **(Previously presented)** The method of claim 70, wherein the antibody is a full length antibody.

128. **(Previously presented)** The method of claim 70, wherein the antibody is a single chain antibody.

129. **(Previously presented)** The method according to claim 71, wherein the subject is human.

130. **(Previously presented)** The method according to claim 71, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

131. **(Previously presented)** The method of claim 71, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

132. **(Previously presented)** The method of claim 71, wherein the antibody is a full length antibody.

133. **(Previously presented)** The method of claim 71, wherein the antibody is a single chain antibody.

134. **(Previously presented)** The method of claim 71, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

135. **(Previously presented)** The method of claim 71, wherein the antibody is conjugated to a chemotherapeutic agent.

136. **(Previously presented)** The method of claim 135, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

137. **(Previously presented)** The antibody of claim 136, wherein the agent is a maytansinoid.

138. **(Previously presented)** The method according to claim 72, wherein the subject is human.

139. **(Previously presented)** The method according to claim 72, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

140. **(Previously presented)** The method of claim 72, wherein the antibody is a humanized antibody.

141. **(Previously presented)** The method of claim 72, wherein the antibody is a human antibody.

142. **(Previously presented)** The method of claim 72, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

143. **(Previously presented)** The method of claim 72, wherein the antibody is a full length antibody.

144. **(Previously presented)** The method of claim 72, wherein the antibody is a single chain antibody.

145. **(Previously presented)** The method of claim 72, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

146. **(Previously presented)** The method of claim 72, wherein the antibody is conjugated to a chemotherapeutic agent.

147. **(Previously presented)** The method of claim 146, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

148. **(Previously presented)** The antibody of claim 147, wherein the agent is a maytansinoid.

149. **(Previously presented)** The method according to claim 73, wherein the subject is human.

150. **(Previously presented)** The method according to claim 73, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

151. **(Previously presented)** The method of claim 73, wherein the antibody is a humanized antibody.

152. **(Previously presented)** The method of claim 73, wherein the antibody is a human antibody.

153. **(Previously presented)** The method of claim 73, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

154. **(Previously presented)** The method of claim 73, wherein the antibody is a full length antibody.

155. **(Previously presented)** The method of claim 73, wherein the antibody is a single chain antibody.

156. **(Previously presented)** The method of claim 73, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

157. **(Previously presented)** The method of claim 73, wherein the antibody is conjugated to a chemotherapeutic agent.

158. **(Previously presented)** The method of claim 157, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

159. **(Previously presented)** The antibody of claim 158, wherein the agent is a maytansinoid.

160. **(Previously presented)** The method according to claim 74, wherein the subject is human.

161. **(Previously presented)** The method according to claim 74, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

162. **(Previously presented)** The method of claim 74, wherein the antibody is a humanized antibody.

163. **(Previously presented)** The method of claim 74, wherein the antibody is a human antibody.

164. **(Previously presented)** The method of claim 74, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

165. **(Previously presented)** The method of claim 74, wherein the antibody is a full length antibody.

166. **(Previously presented)** The method of claim 74, wherein the antibody is a single chain antibody.

167. **(Previously presented)** The method of claim 74, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

168. **(Previously presented)** The method of claim 74, wherein the antibody is conjugated to a chemotherapeutic agent.

169. **(Previously presented)** The method of claim 168, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

170. **(Previously presented)** The antibody of claim 169, wherein the agent is a maytansinoid.

171. **(Previously presented)** The method according to claim 75, wherein the subject is human.

172. **(Previously presented)** The method according to claim 75, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

173. **(Previously presented)** The method of claim 75, wherein the antibody is a humanized antibody.

174. **(Previously presented)** The method of claim 75, wherein the antibody is a human antibody.

175. **(Previously presented)** The method of claim 75, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

176. **(Previously presented)** The method of claim 75, wherein the antibody is a full length antibody.

177. **(Previously presented)** The method of claim 75, wherein the antibody is a single chain antibody.

178. **(Previously presented)** The method of claim 75, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

179. **(Previously presented)** The method of claim 75, wherein the antibody is conjugated to a chemotherapeutic agent.

180. **(Previously presented)** The method of claim 179, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

181. **(Previously presented)** The antibody of claim 180, wherein the agent is a maytansinoid.

182. **(Previously presented)** The method according to claim 76, wherein the subject is human.

183. **(Previously presented)** The method according to claim 76, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

184. **(Previously presented)** The method of claim 76, wherein the antibody is a humanized antibody.

185. **(Previously presented)** The method of claim 76, wherein the antibody is a human antibody.

186. **(Previously presented)** The method of claim 76, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

187. **(Previously presented)** The method of claim 76, wherein the antibody is a full length antibody.

188. **(Previously presented)** The method of claim 76, wherein the antibody is a single chain antibody.

189. **(Previously presented)** The method of claim 76, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

190. **(Previously presented)** The method of claim 76, wherein the antibody is conjugated to a chemotherapeutic agent.

191. **(Previously presented)** The method of claim 190, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

192. **(Previously presented)** The antibody of claim 191, wherein the agent is a maytansinoid.

193. **(Previously presented)** The method according to claim 77, wherein the subject is human.

194. **(Previously presented)** The method according to claim 77, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

195. **(Previously presented)** The method of claim 77, wherein the antibody is a humanized antibody.

196. **(Previously presented)** The method of claim 77, wherein the antibody is a human antibody.

197. **(Previously presented)** The method of claim 77, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

198. **(Previously presented)** The method of claim 77, wherein the antibody is a full length antibody.

199. **(Previously presented)** The method of claim 77, wherein the antibody is a single chain antibody.

200. **(Previously presented)** The method of claim 77, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

201. **(Previously presented)** The method of claim 77, wherein the antibody is conjugated to a chemotherapeutic agent.

202. **(Previously presented)** The method of claim 201, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

203. **(Previously presented)** The antibody of claim 202, wherein the agent is a maytansinoid.

204. **(Previously presented)** The method according to claim 81, wherein the subject is human.

205. **(Previously presented)** The method according to claim 81, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

206. **(Previously presented)** The method of claim 81, wherein the antibody is a humanized antibody.

207. **(Previously presented)** The method of claim 81, wherein the antibody is a human antibody.

208. **(Previously presented)** The method of claim 81, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

209. **(Previously presented)** The method of claim 81, wherein the antibody is a full length antibody.

210. **(Previously presented)** The method of claim 81, wherein the antibody is a single chain antibody.

211. **(Previously presented)** The method of claim 81, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

212. **(Previously presented)** The method of claim 81, wherein the antibody is conjugated to a chemotherapeutic agent.

213. **(Previously presented)** The method of claim 212, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

214. **(Previously presented)** The antibody of claim 213, wherein the agent is a maytansinoid.

215. **(Previously presented)** The method according to claim 82, wherein the subject is human.

216. **(Previously presented)** The method according to claim 82, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

217. **(Previously presented)** The method of claim 82, wherein the antibody is a humanized antibody.

218. **(Previously presented)** The method of claim 82, wherein the antibody is a human antibody.

219. **(Previously presented)** The method of claim 82, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

220. **(Previously presented)** The method of claim 82, wherein the antibody is a full length antibody.

221. **(Previously presented)** The method of claim 82, wherein the antibody is a single chain antibody.

222. **(Previously presented)** The method according to claim 83, wherein the subject is human.

223. **(Previously presented)** The method according to claim 83, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

224. **(Previously presented)** The method of claim 83, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

225. **(Previously presented)** The method of claim 83, wherein the antibody is a full length antibody.

226. **(Previously presented)** The method of claim 83, wherein the antibody is a single chain antibody.

227. **(Previously presented)** The method of claim 83, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

228. **(Previously presented)** The method of claim 83, wherein the antibody is conjugated to a chemotherapeutic agent.

229. **(Previously presented)** The method of claim 228, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

230. **(Previously presented)** The antibody of claim 229, wherein the agent is a maytansinoid.

231. **(Previously presented)** The method according to claim 84, wherein the subject is human.

232. **(Previously presented)** The method according to claim 84, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

233. **(Previously presented)** The method of claim 84, wherein the antibody is a humanized antibody.

234. **(Previously presented)** The method of claim 84, wherein the antibody is a human antibody.

235. **(Previously presented)** The method of claim 84, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

236. **(Previously presented)** The method of claim 84, wherein the antibody is a full length antibody.

237. **(Previously presented)** The method of claim 84, wherein the antibody is a single chain antibody.

238. **(Previously presented)** The method of claim 84, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

239. **(Previously presented)** The method of claim 84, wherein the antibody is conjugated to a chemotherapeutic agent.

240. **(Previously presented)** The method of claim 239, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

241. **(Previously presented)** The antibody of claim 240, wherein the agent is a maytansinoid.

242. **(Previously presented)** The method according to claim 85, wherein the subject is human.

243. **(Previously presented)** The method according to claim 85, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

244. **(Previously presented)** The method of claim 85, wherein the antibody is a humanized antibody.

245. **(Previously presented)** The method of claim 85, wherein the antibody is a human antibody.

246. **(Previously presented)** The method of claim 85, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

247. **(Previously presented)** The method of claim 85, wherein the antibody is a full length antibody.

248. **(Previously presented)** The method of claim 85, wherein the antibody is a single chain antibody.

249. **(Previously presented)** The method of claim 85, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

250. **(Previously presented)** The method of claim 85, wherein the antibody is conjugated to a chemotherapeutic agent.

251. **(Previously presented)** The method of claim 250, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

252. **(Previously presented)** The antibody of claim 251, wherein the agent is a maytansinoid.

253. **(Previously presented)** The method according to claim 86, wherein the subject is human.

254. **(Previously presented)** The method according to claim 86, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

255. **(Previously presented)** The method of claim 86, wherein the antibody is a humanized antibody.

256. **(Previously presented)** The method of claim 86, wherein the antibody is a human antibody.

257. **(Previously presented)** The method of claim 86, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

258. **(Previously presented)** The method of claim 86, wherein the antibody is a full length antibody.

259. **(Previously presented)** The method of claim 86, wherein the antibody is a single chain antibody.

260. **(Previously presented)** The method of claim 86, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

261. **(Previously presented)** The method of claim 86, wherein the antibody is conjugated to a chemotherapeutic agent.

262. **(Previously presented)** The method of claim 261, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

263. **(Previously presented)** The antibody of claim 262, wherein the agent is a maytansinoid.

264. **(Previously presented)** The method according to claim 87, wherein the subject is human.

265. **(Previously presented)** The method according to claim 87, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

266. **(Previously presented)** The method of claim 87, wherein the antibody is a humanized antibody.

267. **(Previously presented)** The method of claim 87, wherein the antibody is a human antibody.

268. **(Previously presented)** The method of claim 87, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

269. **(Previously presented)** The method of claim 87, wherein the antibody is a full length antibody.

270. **(Previously presented)** The method of claim 87, wherein the antibody is a single chain antibody.

271. **(Previously presented)** The method of claim 87, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

272. **(Previously presented)** The method of claim 87, wherein the antibody is conjugated to a chemotherapeutic agent.

273. **(Previously presented)** The method of claim 272, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

274. **(Previously presented)** The antibody of claim 273, wherein the agent is a maytansinoid.

275. **(Previously presented)** The method according to claim 88, wherein the subject is human.

276. **(Previously presented)** The method according to claim 88, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

277. **(Previously presented)** The method of claim 88, wherein the antibody is a humanized antibody.

278. **(Previously presented)** The method of claim 88, wherein the antibody is a human antibody.

279. **(Previously presented)** The method of claim 88, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

280. **(Previously presented)** The method of claim 88, wherein the antibody is a full length antibody.

281. **(Previously presented)** The method of claim 88, wherein the antibody is a single chain antibody.

282. **(Previously presented)** The method of claim 88, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

283. **(Previously presented)** The method of claim 88, wherein the antibody is conjugated to a chemotherapeutic agent.

284. **(Previously presented)** The method of claim 283, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

285. **(Previously presented)** The antibody of claim 284, wherein the agent is a maytansinoid.